Most-Upgraded StocksMost-UpgradedNASDAQ:RVMD Revolution Medicines (RVMD) Stock Price, News & Analysis $206.36 -0.29 (-0.14%) As of 09:57 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Revolution Medicines Stock (NASDAQ:RVMD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Revolution Medicines alerts:Sign Up Key Stats Today's Range$206.60▼$210.2750-Day Range$180.92▼$221.1552-Week Range$45.80▼$224.31Volume128,607 shsAverage Volume2.87 million shsMarket Capitalization$44.23 billionP/E RatioN/ADividend YieldN/APrice Target$234.33Consensus RatingModerate Buy Company Overview Revolution Medicines, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for patients with cancer. The company’s research centers on the RAS signaling pathway, a key driver of tumor growth that is altered in many cancers, including those involving KRAS mutations. Its pipeline includes RAS(ON) inhibitors designed to target active RAS proteins and address a range of RAS-driven tumors. Key development programs include daraxonrasib (RMC-6236), a broad-spectrum RAS inhibitor, and zoldonrasib (RMC-9805), an investigational inhibitor aimed at KRAS G12D-mutated cancers. The company is evaluating these and other candidates in clinical studies across several solid-tumor indications. Founded in 2014 and headquartered in Redwood City, California, Revolution Medicines conducts its drug-discovery and clinical-development activities primarily in the United States. The company is led by Mark A. Goldsmith, who serves as chairman and chief executive officer.AI Generated. May Contain Errors. Read More Revolution Medicines Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreRVMD MarketRank™: Revolution Medicines scored higher than 65% of companies evaluated by MarketBeat, and ranked 324th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingRevolution Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.96, and is based on 2 strong buy ratings, 20 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialRevolution Medicines has a consensus price target of $234.33, representing about 13.4% upside from its current price of $206.64.Amount of Analyst CoverageRevolution Medicines has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Revolution Medicines' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Revolution Medicines are expected to grow in the coming year, from ($8.87) to ($6.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revolution Medicines is -23.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Revolution Medicines is -23.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRevolution Medicines has a P/B Ratio of 24.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Revolution Medicines' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.88% of the float of Revolution Medicines has been sold short.Short Interest Ratio / Days to CoverRevolution Medicines has a short interest ratio ("days to cover") of 7.24.Change versus previous monthShort interest in Revolution Medicines has recently decreased by 0.60%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRevolution Medicines does not currently pay a dividend.Dividend GrowthRevolution Medicines does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.66 News SentimentRevolution Medicines has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Revolution Medicines this week, compared to 8 articles on an average week.Search InterestOnly 16 people have searched for RVMD on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.MarketBeat Follows21 people have added Revolution Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 110% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Revolution Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $59,422,765.00 in company stock.Percentage Held by Insiders7.60% of the stock of Revolution Medicines is held by insiders.Percentage Held by Institutions94.34% of the stock of Revolution Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Revolution Medicines' insider trading history. Receive RVMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RVMD Stock News HeadlinesRevolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer1 hour ago | globenewswire.comRevolution Medicines (NASDAQ: RVMD) CDO sells 6,309 shares under preset planOctober 5 at 4:02 AM | americanbankingnews.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 5 at 1:00 AM | Profits Run (Ad)Revolution Medicines: Priced For A Label The Trial Didn't Test; HoldOctober 3 at 9:34 AM | seekingalpha.comInsider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells 341 Shares of StockSeptember 19, 2026 | insidertrades.comRevolution Medicines (NASDAQ:RVMD) Insider Stephen Michael Kelsey Sells 92,531 SharesSeptember 16, 2026 | insidertrades.comMarketBeat Week in Review – 09/07 - 09/11 (RVMD)Stocks fell this week on oil prices and Fed rate-hike expectations, though Oracle's earnings underscored AI infrastructure strength. MarketBeat analysts recap top stories on earnings, defense, AI, and other stock opportunities.September 12, 2026 | marketbeat.comLorence Kim Sells 17,090 Shares of Revolution Medicines (NASDAQ:RVMD) StockSeptember 11, 2026 | insidertrades.comSee More Headlines RVMD Stock Analysis - Frequently Asked Questions How have RVMD shares performed this year? Revolution Medicines' stock was trading at $79.65 on January 1st, 2026. Since then, RVMD shares have increased by 159.4% and is now trading at $206.64. How were Revolution Medicines' earnings last quarter? Revolution Medicines, Inc. (NASDAQ:RVMD) issued its quarterly earnings data on Wednesday, August, 5th. The company reported ($3.06) EPS for the quarter, missing the consensus estimate of ($2.04) by $1.02. Read the conference call transcript. When did Revolution Medicines IPO? Revolution Medicines (RVMD) raised $231 million in an IPO on Thursday, February 13th 2020. The company issued 14,000,000 shares at $16.00-$17.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO. Who are Revolution Medicines' major shareholders? Revolution Medicines' top institutional shareholders include Burkett Financial Services LLC. Insiders that own company stock include Thilo Schroeder, Stephen Michael Kelsey, Mark A Goldsmith, Margaret A Horn, Jack Anders, Xiaolin Wang, Lin Wei, Alan B Sandler, Jeff Cislini, Sushil Patel, Barbara Weber, Elizabeth M Anderson and Lorence H Kim. View institutional ownership trends. How do I buy shares of Revolution Medicines? Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Revolution Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Revolution Medicines investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings8/05/2026Today10/05/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 RVMD's financial health is in the Green zone, according to TradeSmith. RVMD has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RVMD CIK1628171 Webwww.revmed.com Phone650-481-6801FaxN/AEmployees883Year Founded2014Price Target and Rating Average Price Target for Revolution Medicines$234.33 High Price Target$320.00 Low Price Target$80.00 Potential Upside/Downside+13.3%Consensus RatingModerate Buy Rating Score (0-4)2.96 Research Coverage24 Analysts Profitability EPS (Trailing Twelve Months)($8.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.13 billion Net MarginsN/A Pretax MarginN/A Return on Equity-88.20% Return on Assets-57.85% Debt Debt-to-Equity Ratio0.40 Current Ratio11.38 Quick Ratio11.38 Sales & Book Value Annual Sales$11.58 million Price / Sales3,828.06 Cash FlowN/A Price / Cash FlowN/A Book Value$8.44 per share Price / Book24.50Miscellaneous Outstanding Shares214,340,000Free Float198,046,000Market Cap$44.33 billion OptionableOptionable Beta1.40 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:RVMD) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revolution Medicines With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
